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Abstract
Inflammation is a key feature of atherosclerosis and a target for therapy. Statins have potent anti-
inflammatory properties but these cannot be fully exploited with oral statin therapy due to low
systemic bioavailability. Here we present an injectable reconstituted high-density lipoprotein
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t(rHDL) nanoparticle carrier vehicle that delivers statins to atherosclerotic plaques. We
demonstrate the anti-inflammatory effect of statin-rHDL in vitro and show this effect is mediated
through inhibition of the mevalonate pathway. We also apply statin-rHDL nanoparticles in vivo in
an apolipoprotein E-knockout mouse model of atherosclerosis and show they accumulate in
atherosclerotic lesions where they directly affect plaque macrophages. Finally we demonstrate that
a three-month low-dose statin-rHDL treatment regimen inhibits plaque inflammation progression,
while a one-week high-dose regimen markedly decreases inflammation in advanced
atherosclerotic plaques. Statin-rHDL represents a novel potent atherosclerosis nanotherapy that
directly affects plaque inflammation.
Introduction
Atherosclerotic diseases, such as acute myocardial infarction, are a major cause of death and
disability worldwide [http://www.who.int/cardiovascular_diseases/en/]. Preventive strategies
currently focus on controlling risk factors, such as smoking, blood pressure, serum glucose
and lipid levels1. Despite the success of these preventive measures, substantial residual risk
remains even when treatment goals are fully met2. In patients that suffered a myocardial
infarction the recurrence risk of an acute coronary syndrome is high, particularly within the
first year when recurrence rates are up to 17.4%3. A recent study explained this phenomenon
by showing that a systemic response to ischemic injury aggravates inflammation in
atherosclerotic plaques at a distance, due to increased monocyte recruitment4. Monocytes
that infiltrate the plaque differentiate into macrophages, which produce proteolytic enzymes
that digest extracellular matrix causing plaque rupture5. The immediate site of plaque
rupture contains a high concentration of inflammatory cells6. Plaque inflammation is
therefore pursued as a therapeutic target to prevent atherothrombotic events7.
In the current study we developed a nanomedicine-based delivery strategy based on
reconstituted high density lipoprotein (rHDL) nanoparticles that allow for drug delivery to
atherosclerotic plaques. As a cargo for our rHDL nanoparticles we selected a 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGR) inhibitor, or statin. Statins are widely orally
prescribed serum low density-lipoprotein (LDL) cholesterol-lowering drugs that upregulate
LDL receptor expression in hepatocytes8. In addition to its effect on hepatocytes, various
studies have established the potent immunomodulating effects of HMGR inhibition in
inflammatory cells9–11. In an atherosclerotic mouse model in which statins did not affect
lipid levels, reduced plaque formation was shown with extremely high doses of oral statin
therapy12. However, in humans increasing the oral statin dose to attain higher plasma
concentrations is not feasible due to the dose-dependent onset of adverse effects such as
hepatoxicity and myopathy13. Normal doses of orally ingested statins hardly enter the
systemic circulation as biotransformation occurs in the liver14.
We addressed this issue by developing a statin-loaded rHDL nanoparticle ([S]-rHDL) that
can be administered intravenously, augments bioavailability, and facilitates the delivery of
statins to atherosclerotic plaque. We show, in an apolipoprotein E-knockout (apoE-KO)
mouse model of atherosclerosis, that a three-month low dose- as well as a one-week high
dose [S]-rHDL treatment regimen markedly reduces plaque macrophage content.
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Study summary
A schematic overview of the study design is shown in Fig 1. First, we studied [S]-rHDL’s
characteristics and its efficacy in different cell lines in vitro. Subsequently, biodistribution
and toxicity, as well as uptake by atherosclerotic plaque macrophages were investigated in
mouse models in vivo. Next, we investigated the in vivo efficacy of a low dose long-term
[S]-rHDL infusion regimen on plaque development and a short-term high dose infusion
regimen on plaque regression in apoE-KO mice.
[S]-rHDL characteristics
We constructed [S]-rHDL from recombinant human apolipoprotein A-1 (ApoA-1), the
phospholipids 1-myristoyl-2-hydroxy-sn-glycero-phosphocholine (MHPC) and 1,2-
dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC), in which lipophilic simvastatin was
encapsulated. This resulted in discoid-shaped nanoparticles of 25 to 30 nm in diameter as
determined by dynamic light scattering and transmission electron microscopy (Fig. 2a,
Supplementary Fig. S1, and Supplementary Table S1). Its exact composition was established
by phosphate determinations and simvastatin measurements by high-performance liquid
chromatography (Supplementary Table S1). Stability experiments with the free drug and the
[S]-rHDL nanoparticle formulation in mouse serum demonstrated the protective function of
the rHDL nanoparticle towards statin degradation (Supplementary Fig. S2). To allow its
visualization in cells and tissue via imaging techniques we also synthesized a variant where
an amphiphilic MRI contrast agent, gadolinium - diethylene triamine pentaacetic acid-
distearyl amide (Gd-DTPA-DSA) and/or fluorescent dyes (Cy5.5, DiO or DiR) were
incorporated (Fig. 2a).
In vitro efficacy of [S]-rHDL
To assess [S]-rHDL’s therapeutic potential and function we investigated its anti-
inflammatory effect in vitro. First, we investigated the effect of [S]-rHDL on viability of
murine macrophages (J774A.1) as well as on hepatocytes, endothelial cells and smooth
muscle cells as function of incubation concentration and time. Cells were incubated with
rHDL or [S]-rHDL, with statin doses of 1 μM, 10 μM and 100 μM (Supplementary Fig. S3).
Macrophage survival was comparable in the rHDL and [S]-rHDL incubated cells at 6 and 12
hour time points, while macrophage survival decreased in the [S]-rHDL incubated cells at
24 and 48 hours. A similar response was observed in cultured endothelial cells. Significantly
less loss in cell viability was observed for the smooth muscle cells and hepatocytes
(Supplementary Fig. S3). Subsequently, we investigated if the effect of [S]-rHDL on
macrophage cell viability was mediated through the mevalonate pathway. In macrophages
incubated with [S]-rHDL or free statin (10 μM), we observed a nearly complete loss of cell
viability at 48 hours incubation time, while this did not occur in cells incubated with rHDL.
This effect was abolished when mevalonate was added to [S]-rHDL or free statin (Fig. 2b).
Next, we evaluated [S]-rHDL’s effect on the expression of inflammatory cytokines (Fig. 2c).
We first stimulated the macrophages with LPS and IFN-γ for 16 hours. Cell viability at
these conditions was not markedly affected. We then treated the cells with different
treatments for 24 hours in serum-free condition, and assessed expression of the anti-
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tinflammatory markers monocyte chemotactic protein-1 (MCP-1) and tumor necrosis factor-
α (TNF-α). We observed a decrease in expression of MCP-1 and TNF-α in macrophages
treated with [S]-rHDL or free statins. The expression of MCP-1 and TNF-α was restored by
the addition of mevalonate in macrophages treated with [S]-rHDL and free statins (Fig. 2c).
Cell viability of macrophages treated with [S]-rHDL was similar to control cells
(Supplementary Fig. S4). These data show that [S]-rHDL reduces cell viability and the
production of inflammatory cytokines by inhibiting the mevalonate pathway. Subsequently,
we investigated the mechanism by which [S]-rHDL decreases macrophage cell viability. We
observed that [S]-rHDL decreased macrophage proliferation. We also observed that [S]-
rHDL causes non-apoptotic macrophage cell death (Supplementary Fig. S4).
In vivo biodistribution and toxicity studies
To investigate [S]-rHDL’s biodistribution we designed an [S]-rHDL nanoparticle that
carried 2 labels, namely Cy5.5 conjugated to a phospholipid and the hydrophobic dye DiO
or DiR. Cy5.5-phospholipids incorporated in the corona, while the hydrophobic dyes DiO /
DiR were incorporated in the simvastatin-loaded core of [S]-rHDL (Fig. 2a). Lipoproteins,
including HDL, are dynamic systems that are known to exchange lipid components15–17.
Therefore, we hypothesized that the hydrophobic DiO / DiR core label would display a
different kinetic behaviour from the amphiphilic phospholipid-Cy5.5 corona label. To
investigate this, we injected apoE-KO mice (N=21) with the dual-labelled [S]-rHDL,
sacrificed at different time points (N=3 per time point), and collected the blood, hearts,
aortas, spleens, livers and kidneys. The blood was separated into three fractions, i.e. plasma,
mononuclear cells (MNC) and red blood cells (RBC). We observed that the majority of the
Cy5.5 labelled phospholipids remained in the plasma fraction of the blood, while a small
fraction was transferred to the RBC (Fig. 3a and b). The core label DiO was detectable in the
serum fraction only and displayed longer circulation kinetics. Further analysis of blood by
flow cytometry revealed the small fraction of DiO associated with MNC to be most
abundantly present in pro-inflammatory Gr-1hi monocytes (Fig. 3c, Supplementary Fig. S5).
Near infrared fluorescence (NIRF) imaging and fluorescence microscopy of the spleen, liver
and kidneys revealed the highest DiR presence in liver tissue (Supplementary Fig. S6).
Nanoparticles were found in heart, aorta, liver, spleen, and kidney tissue, but not in muscle
tissue (Supplementary Fig. S6). A combination of restricted nanoparticle accessibility from
the muscle microvasculature to muscle tissue and the absence of SR-B1, ABCA-1 or
ABCG-1 expression may explain why our nanoparticle were not found associated with
myocytes. In the spleen, DiR signal co-localized with CD68-stained monocytes/
macrophages (Supplementary Fig. S7). Flow cytometry analysis of spleen cells revealed that
macrophages and Ly-6chi (Gr-1hi) monocytes took up [DiO-S]-rHDL most efficiently, while
neutrophils and Ly-6clo (Gr-1hi) moncoytes took up markedly less nanoparticles. [S]-rHDL
did not exert toxic effects on liver, kidney or myocytes when it was administered to mice at
a high dose (60 mg/kg simvastatin, 40 mg/kg ApoA-1, 4 intravenous infusion / week) for a
week (Supplementary Fig. S8).
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To assess whether our nanoparticles accumulated in atherosclerotic lesions and was taken up
by plaque macrophages, we conducted two experiments. In the first experiment, apoE-KO
mice on a high cholesterol diet for 28 weeks, were infused with gadolinium and statin
containing rHDL ([Gd-S]-rHDL, N=3), or placebo (N=3). In vivo MRI experiments
performed with a 9.4 Tesla scanner revealed signal enhancement in the vessel wall on T1-
weighted images 24 hours after infusion of [Gd-S]-rHDL, indicating pronounced
accumulation of our nanoparticle in the vessel wall (Fig. 2d).
In the second experiment dual-labelled [S]-rHDL, with Cy5.5-phospholipids in the corona
and DiO / DiR in the core, were injected in apoE-KO mice. 24 hours post-injection, the mice
were sacrificed and the hearts and aortas were excised. The distribution of DiR labelled [S]-
rHDL in intact aortas was investigated by NIRF imaging and revealed its accumulation in
regions rich in plaques (Fig. 3e). The targeting kinetics of DiO (the core label) and Cy5.5-
phospholipid label displayed a pattern similar to the blood kinetics (Fig. 3f), namely that the
Cy5.5-labelled phospholipids appeared in the plaque until 4 hours post injection after which
their presence declined. In contrast, the DiO core label was retained in the plaque up to at
least 24 hours. Furthermore, fluorescence microscopy of plaques revealed co-localization of
DiO-labelled [S]-rHDL with macrophages in the aortic root (Fig. 3g). Flow cytometry of
cells from atherosclerotic plaques showed that the fluorescence intensity of the core label
DiO was 5–6 fold stronger in macrophages (MΦ) than in freshly recruited monocytes (Mo)
(Fig. 3h, Supplementary Fig. S5).
In vivo efficacy of low dose [S]-rHDL infusions
To investigate the effect of [S]-rHDL on plaque inflammation we used apoE-KO mice
(N=74) that were on a high cholesterol diet for 14 weeks in order to develop atherosclerosis.
Statins are known not to affect blood cholesterol levels of apoE-KO mice, because they lack
the major ligand for the LDL receptor, namely apoE18,19, and also metabolize statins very
fast in their livers20, making this a suitable model to solely investigate the anti-inflammatory
effects of HMGR inhibition. To limit a dominant therapeutic effect of rHDL itself, we used
a low ApoA-1 dose. While the mice remained on the high cholesterol diet, they received bi-
weekly infusions of [S]-rHDL (15 mg/kg statin, 10 mg/kg ApoA1, N=16), placebo (saline
infusion, N=15), orally dosed statin (15 mg/kg statin daily, N=15) or bi-weekly infusion of
bare rHDL nanoparticles (10 mg/kg ApoA1, N=15) for 12 consecutive weeks. We also
included a group of mice that were sacrificed when the other groups started their treatment,
which we refer to as the baseline group (N=12). As plaque formation in apoE-KO mice
occurs more rapidly in the aortic root than in the abdominal aorta we were able to study the
effects of [S]-rHDL in both early and established atherosclerotic lesions. In the aortic root
plaque formation is reproducible, consistent and homogenous, and covers a length of less
than 0.5 mm, which enables us to apply quantitative histology analyses. We evaluated 42
cross-sections of the aortic sinus area per mouse. This resulted in the analysis of 3108 cross-
sections in total. Cross-sections were stained for connective tissue with hematoxylin
phloxine saffron (HPS) or immunostained with CD68 antibodies to visualize macrophages.
We developed a quantitative and digitized method with in-house developed software
(Matlab) for the analysis of the histology images, to quantify total plaque area (macrophages
Duivenvoorden et al. Page 5
Nat Commun. Author manuscript; available in PMC 2014 July 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tplus connective tissue) and macrophage rich area (Supplementary Fig. S9). In contrast to the
development of atherosclerosis in the aortic root, plaque formation in the abdominal aorta is
heterogeneous and covers a length of 2 cm, which excludes histological analysis for an
accurate assessment. Instead we performed longitudinal in vivo 9.4 T MRI in a subset of
mice (N=40, 7–9 per group, Supplementary Fig. S10). Examples of histological sections of
the abdominal aorta are displayed in Supplementary Fig. S11.
Our in vivo MRI data showed that compared to the [S]-rHDL-treated group, vessel wall
thickness was 16% higher in the placebo group (Mann-Whitney U test p=0.01), 12% higher
in the oral statin group (Mann-Whitney U test p=0.004), and 16% higher in the rHDL group
(Mann-Whitney U test p=0.005, Fig. 4a, b) at the end of the study.
Subsequently, all mice (N=74) were sacrificed and atherosclerotic burden was quantified by
means of histology of the aortic sinus. Total plaque area in the [S]-rHDL group was
significantly decreased by 34% compared to the baseline group (Mann-Whitney U test
p<0.001), by 37% compared to placebo (Mann-Whitney U test p=0.002), and by 28%
compared to rHDL (Mann-Whitney U test p=0.006, Fig. 4c). The [S]-rHDL group showed a
trend towards a decrease of 17% compared to the oral statin group (Mann-Whitney U test
p=0.06, Fig. 4c). Plaque macrophage content was markedly decreased in the [S]-rHDL
group by 56% compared to the baseline group (Mann-Whitney U test p<0.001), by 57%
compared to placebo (Mann-Whitney U test p=0.001), by 37% compared to oral statin
(Mann-Whitney U test p=0.003), and by 40% compared to rHDL (Mann-Whitney U test
p=0.03, Fig. 4d). In Fig. 4e typical and representative histological sections of the different
groups are shown.
We also quantified the cholesterol content of the thoracic aortas of all mice (N=74), by
digesting the excised aortas followed by chemical quantification of the cholesterol content.
In line with expectation, we did not observe any differences in aorta cholesterol content
across all groups (Supplementary Fig. S12).
Serum triglyceride and total cholesterol levels did not differ significantly across all groups,
although total cholesterol had the tendency to be higher in the placebo and rHDL groups
(Supplementary Fig. S13). Total cholesterol levels were equal in the oral statin and [S]-
rHDL groups, however, fast-performance liquid chromatography showed that the oral statin
group had a more favorable lipid profile than the [S]-rHDL group, with 31% lower VLDL,
16% lower LDL and 37% higher HDL cholesterol (Supplementary Fig. S14). The decrease
in plaque macrophage area by [S]-rHDL remained significant compared to placebo
(Multiple linear regression analysis p=0.002), oral statin (Multiple linear regression analysis
p=0.01), and rHDL (Multiple linear regression analysis p=0.02) after statistical adjustment
for serum total cholesterol levels.
In vivo efficacy of high dose [S]-rHDL infusions
To assess the effect of short term high dose [S]-rHDL therapy on plaque inflammation,
apoE-KO mice that had developed advanced atherosclerotic lesions after 27 weeks of the
high cholesterol diet, were administered high dose [S]-rHDL (60 mg/kg statin, 40 mg/kg
ApoA1, N=7), placebo (saline infusion, N=15), high dose rHDL (40 mg/kg ApoA1, N=8),
Duivenvoorden et al. Page 6
Nat Commun. Author manuscript; available in PMC 2014 July 01.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tor low dose [S]-rHDL (15 mg/kg statin, 10 mg/kg ApoA1, N=10). All mice (N=40) received
four infusions of their assigned therapy within a single week. Histological assessment of the
aortic sinus area was performed as described before (Supplementary Fig. S9), and a total of
1680 cross sections were analyzed. Histology showed a trend towards a decrease of 31% in
total plaque area in the high dose [S]-rHDL-group compared to placebo (Mann-Whitney U
test p=0.053), and was decreased by 34% compared to high dose rHDL (Mann-Whitney U
test p=0.005), and by 36% compared to the low dose [S]-rHDL-group (Mann-Whitney U
test p=0.006, Fig. 5a). The decrease in total plaque area primarily accounted for the
decreased macrophage positive areas in the high dose [S]-rHDL-group. It was decreased by
84% when compared to placebo (Mann-Whitney U test p<0.001), by 79% compared to high
dose rHDL (Mann-Whitney U test p=0.001), and 77% compared to low dose [S]-rHDL
(Mann-Whitney U test p=0.002, Fig. 5b). In Fig. 5c typical and representative histological
sections of the different groups are shown. Serum triglyceride and total cholesterol levels
were equal across all groups (Supplementary Fig. S15). The difference in plaque
macrophage content between the [S]-rHDL group and placebo (Multiple linear regression
analysis p<0.001), oral statin (Multiple linear regression analysis p<0.001), and rHDL
(Multiple linear regression analysis p=0.004) remained significant after statistical
adjustment for serum total cholesterol levels.
In a subsequent study, also in apoE-KO mice (N=36) with advanced atherosclerosis, we
determined the mRNA expression levels of genes related to inflammation in plaque
macrophages by means of laser capture microdissection (LCM). We compared mice treated
with high dose [S]-rHDL, to mice treated with oral statin therapy, and placebo (Fig. 5d,
Supplementary Fig. S16). We observed that in the high dose [S]-rHDL group, mRNA
expression levels of monocyte recruitment genes (MCP-1, CCL-3, ICAM-1, VCAM-1,
CCL-15, CXCL-12), as well as those of pro-inflammatory genes (TNF-α, IL-1β, IL-1α,
SPP-1), were markedly decreased as compared to the oral statin and placebo groups (Fig.
5d). The anti-inflammatory mannose receptor (MR) mRNA level was increased in the high
dose [S]-rHDL group as compared to placebo, but was similar to the oral simvastatin group
(Fig. 5d).
Finally, to corroborate these findings we performed in vivo fluorescence molecular
tomography with computed tomography (FMT-CT) imaging to visualize and measure the
protease activity in the aortic roots of another 11 apoE-KO mice. We revealed that the
inflammatory protease activity was markedly reduced in apoE-KO mice treated with [S]-
rHDL as compared to placebo (Fig. 5e). Together these data demonstrate the potent local
anti-inflammatory effect of [S]-rHDL in atherosclerotic plaques.
Discussion
In the current study we described the development of a statin-rHDL nanoparticle as a
therapy for reducing atherosclerotic plaque inflammation. The key findings of our study are
that this compound (1) suppresses the inflammatory response of macrophages which is
mediated through the inhibition of intracellular mevalonate pathway, (2) accumulates in
atherosclerotic plaque where it is taken up by macrophages, (3) markedly reduces plaque
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tmacrophage content and inflammation following both prolonged low dose therapy as well as
short-term high dose therapy, and (4) does not exhibit myo- or hepatotoxic effects.
The platform on which we based our nanoparticle is rHDL. Traditionally, HDL is
considered to remove excess cholesterol from peripheral tissues and transport it to the liver
for fecal excretion, a process referred to as the “reverse cholesterol transport”21,22. For this
reason previous studies have investigated rHDL as a therapeutic agent. Shah et al. showed
that in apoE-KO mice, 18 infusions of 40 mg/kg ApoA1 within 5 weeks had no effect on
plaque size, but reduced plaque lipid content by 40%, and plaque macrophage content by
46%23. In another study, Shah et al. showed in apoE- KO mice that a single injection of 400
mg/kg ApoA1 reduced plaque lipid content by 40–50% and plaque macrophage content by
29–36%24. It is important to note that in the current study we did not aim at employing
rHDL and ApoA1 as a therapeutic agent, apart from its ability to deliver statin to plaque
tissue. Compared to the studies by Shah et al. we used lower ApoA1 doses, namely 24
infusions of 10mg/kg in the 3 months low dose study and 4 infusions of 40 mg/kg ApoA1 in
the single week high dose study. In both our low- and high dose study plaque size was
unchanged in the rHDL-group as compared to placebo, but plaque macrophage content
tended to be lower in the rHDL-groups as compared to placebo. Despite this, we were able
to show a marked reduction in plaque macrophage content by [S]-rHDL treatment compared
to the rHDL-group. rHDL infusion has also been investigated in large randomized controlled
trials in humans25,26. Although the therapeutic efficacy was disappointing, the ApoA1 doses
of 40 mg/kg used in these studies were well tolerated. This shows that the ApoA1 doses of
10 mg/kg and 40 mg/kg that we used can safely be translated to future human studies.
In addition to HDL’s ability to remove excess cholesterol from atherosclerotic plaques,
native HDL also transports proteins involved in inflammation, coagulation, complement
activation27, and endogenous micro RNAs, and delivers them to recipient cells28. This
indicates that native HDL is in fact a carrier vehicle involved in complex intercellular
communication. In the current study we utilize this natural property of HDL to act as a
delivery vehicle of statins to target macrophages in atherosclerotic lesions. We showed that
rHDL protects the statin cargo from catabolism in the serum, increases statin’s
bioavailability, and delivers its cargo to plaques where it is taken up by plaque macrophages.
Our data on pharmacokinetics demonstrate that in the circulation [S]-rHDL is predominantly
located in the plasma, and a small sub-fraction in blood monocytes. Blood monocytes that
took up [S]-rHDL in the circulation and subsequently infiltrated the plaque, could
potentially account for some of the accumulation of [S]-rHDL in the plaque. However,
direct infiltration from the plasma into the plaque most likely accounts for the majority of
[S]-rHDL accumulation in plaques. The reason why, within the vasculature, [S]-rHDL
preferentially accumulates at sites of atherosclerotic lesions is likely related to local
endothelial permeability, which facilitates infiltration of the nanoparticle into the vascular
tissue, after which it is retained due to ingestion by macrophages. We did not investigate the
mechanism by which plaque macrophages take up [S]-rHDL. Native HDL is known to
interact with macrophages through scavenger receptor B1, and adenosine triphosphate
binding cassette transporter A1 and G121,22. Possibly our nanoparticle has a similar
interaction or is simply phagocytosed by macrophages.
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local anti-inflammatory effects. The immunomodulating effects of statins have been
established in previous studies, which showed that HMGR inhibition reduces the production
of downstream isoprenoid intermediates (e.g. farnesyl pyrophosphate) in the intracellular
cholesterol synthesis pathway, which decreases the isoprenylation of proteins29,30. This
interferes with the attachment of proteins to the cell membrane, which affects proliferation
and function of inflammatory cells, such as macrophages9–11. In the current study we
confirm the anti-inflammatory effect of statins both in vitro and in vivo. In vitro, we show
that the anti-inflammatory effect remains equally potent when statin is encapsulated in
rHDL as compared to free statin. We also demonstrate that the anti-inflammatory effects of
statins are mediated through the inhibition of the mevalonate pathway, which corroborates
results from previous studies9–11.
A previous study in an atherosclerotic mouse model investigated the effects of oral statin
therapy on atherogenesis. Sparrow et al. treated apoE-KO mice daily with 100 mg/kg
simvastatin for 6 weeks, and showed marked reduction in aortic plaque development despite
the fact that statin therapy did not affect serum lipid levels12. They also showed effects of
their high dose oral statin therapy on carrageenan-induced foot pad edema, a model of
inflammation. They did not investigate the mechanism by which atherogenesis and
inflammation was reduced, but it is conceivable that higher than normal serum levels of
statins were achieved since their oral statin dose was extremely high. In humans it is not
possible to administer such high oral doses due to adverse effects13. In the current study we
used a lower oral statin dose than that used by Sparrow et al., namely 15 mg/kg in the 3
months low dose study. Plaque size and macrophage content tended to be lower in the oral
statin group compared to placebo. Nonetheless, we showed a marked reduction in plaque
inflammation with [S]-rHDL treatment, despite 3.5 times lower weekly doses of statin in
[S]-rHDL-group (15 mg/kg simvastatin, 2 times / week) than that in oral statin-group (15
mg/kg simvastatin / day).
In addition to the decrease in plaque macrophage content following [S]-rHDL treatment, we
were able to show that [S]-rHDL markedly affects plaque macrophage mRNA expression
levels of genes related to inflammation. Furthermore, we observed that short-term high-dose
[S]-rHDL treatment markedly decreased inflammatory protease activity in atherosclerotic
plaques, which was measured in vivo with FMT-CT.
Of note, in the current study we focused on the anti-inflammatory effect of our nanoparticle,
since statins do not affect serum lipid levels in this mouse model. However, we showed that
in the mice nanoparticles were taken up in the liver. In humans [S]-rHDL will undoubtedly
also be taken up by hepatocytes, where the delivered statin will up-regulate the LDL-
receptor expression. Thus in humans, our nanoparticle may have two therapeutic effects,
namely an anti-inflammatory effect on plaques as well as a cholesterol lowering effect due
to its effect on hepatocytes.
The clinical implications of our findings pertain to the field of cardiovascular disease. With
current standard of care therapy, recurrent angina before discharge occurs in up to 10% of
patients following an acute coronary syndrome, and recurrent acute coronary syndrome
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twithin the first year in 17.4% of patients3. Therefore novel therapeutic strategies like rHDL
infusion are being developed, with the concept to initiate therapy directly after the acute
event in an effort to rapidly decrease plaque vulnerability. Unfortunately, the efficacy of
rHDL infusion alone so far has been disappointing25,26. Extrapolating from the evidence
provided, we envision that [S]-rHDL nanotherapy can facilitate plaque retention of high
quantities of statin following short-term intravenous administration in acute coronary
syndrome patients, thereby modulating plaque inflammation31. This holds promise to
suppress plaque inflammation during the vulnerable period following acute coronary
syndrome, which can support standard-of-care therapy to prevent recurrent plaque rupture
and atherothrombotic events. An advantage of nanotherapy we present is that the individual
components are well tolerated by humans. Statins are prescribed routinely to millions of
patients worldwide, whereas rHDL in lower concentrations has proven to be safe in large
phase IIB trials13,25,26. In our study we did not observe myo- or hepatotoxicity of our
nanoparticle. Therefore, [S]-rHDL represents a novel anti-atherosclerotic nanotherapy with a
high potential for clinical translation.
In conclusion, [S]-rHDL nanotherapy locally treats atherosclerotic inflammation at the level
of the vessel wall. The potency of the treatment allows for the inhibition of plaque
inflammation using a long-term, low-dose treatment regimen, while a short-term, high-dose
treatment regimen can be applied to rapidly deplete inflammation in advanced
atherosclerotic plaques.
Methods
Synthesis of [S]-rHDL
The synthesis of [S]-rHDL was modified from a published method32. Briefly, simvastatin
(AKscentific), 1-myristoyl-2-hydroxy-sn-glycero-phosphocholine (MHPC) and 1, 2-
dimyristoyl-sn-glycero-3-phosphatidylcholine (DMPC) (both purchased from Avanti Polar
Lipids) were dissolved in chloroform/methanol (4:1 by volume) solvent and dried to form
thin film. Human apolipoprotein A1 proteins (ApoA-1) (CSL, Parkville, Australia) dissolved
in PBS was added to the film and the solution was incubated in 37°C till the film was
hydrated and a homogenous solution was formed. The solution was sonicated to form small
[S]-rHDL nanoparticles. Aggregates were removed by centrifugation and filtration.
Gadolinium-DTPA-DMPE (Avanti Polar Lipids), Cy5.5-DMPE (DMPE was conjugated
with Cy5.5 NHS-ester purchased from GE healthcare), DiR or DiO (Invitrogen) were added
when the nanoparticles were subsequently used for imaging purposes. Control rHDL
nanoparticles without simvastatin were synthesized with the same procedures.
Characterization of [S]-rHDL
Nanoparticles were negatively stained with a method previously reported33. Images were
acquired using a Hitachi H7650 system linked to a SIA (Scientific Instruments and
Applications) digital camera controlled by Maxim CCD software. The mean size of the
different formulations of nanoparticles was determined by dynamic light scattering
(Brookhaven Instruments Corporation, Holtsville, NY) and by measuring the nanoparticles
in transmission electron microscopy (TEM) images. The percentage of phospholipids in the
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tnanoparticles was determined by Rouser’s method; the percentage of simvastatin by high
performance liquid chromatography (HPLC) (Shimadzu HPLC instrument); the percentage
of protein by a BCA protein concentration assay (Bio Rad); The longitudinal relaxivity (r1)
of gadolinium loaded [S]-rHDL ([Gd-dye-S]-rHDL) were measured on a 60 MHz Bruker
Minispec (Bruker Medical BmbH, Ettingen) operating at 40 °C. To determine the half-life of
encapsulated simvastatin in [S]-rHDL, a concentration of 1000 μg/ml of simvastatin from
[S]-rHDL or free simvastatin was achieved in mouse serum and the solution was kept at 37
°C. The concentration of intact simvastatin in the serum at different time points was
measured with HPLC) (Shimadzu HPLC equipped with a column (Ascentis C18, 10 cm x
4.6 mm I.D., 3 μm particles (581321-U) Reversed phase), using a protocol adapted from the
published one34. The mobile phase was 80% Acetonitrile and 20% H2O and flow rate was
0.5 ml/min. The half-life of simvastatin in [S]-rHDL and free simvastatin was defined as the
length of incubation time when the serum simvastatin concentration was 500 μg/ml.
In vitro cell assays
J774A.1 (murine macrophages), MS1 (murine endothelial cells), MOVAS (murine aortic
smooth muscle cells) and Hepa-1c1c7 (murine liver cells) were cultured under ATCC-
recommended conditions. [S]-rHDL nanoparticles were added to the cells to reach different
concentrations of simvastatin in cell culture, whereas rHDL nanoparticles were added to
reach the same ApoA-1 concentrations as [S]-rHDL in each condition, and mevalonate was
added to reach 100 μM when needed. The cell viability was determined by measuring
intracellular ATP concentration by following the manufacturer’s instructions (Promega,
CellTiter Glo). To measure MCP-1 and TNF-α production by J774A.1 cells, the cells were
first challenged with LPS and IFN-γ for 16 hours, and subsequently switched to serum-free
culture condition and treated with [S]-rHDL, free simvastatin, rHDL or nothing for another
24 hours at the concentration of 10 μM simvastatin or equal concentration of ApoA-1 from
rHDL, in the presence or absence of 100 μM mevalonate. TNF-α and MCP-1 concentrations
in the supernatants were measured with ELISA by following the manufacturer’s instructions
(Biolegend).
For apoptosis/necrosis assay, murine cells (J774A.1) were treated with 10 μM simvastatin
equivalent [S]-rHDL for 24 hours, and then stained with either apoptosis specific dye (YO-
PRO-1) or necrosis specific dye (Propidium iodide). Measurement was used following
manufacture’s instruction (life technologies, Cat# V13243). In brief, apoptotic cells are
defined as YO-PRO-1 positive Propidium iodide positive on flow cytometry graph, while
necrosis cells are YO-PRO-1 negative Propidium iodide positive. For cell proliferation,
assay was done by following the manufacturer’s instruction (life technologies, Cat#
C34554). In brief, macrophages were incubated with 5 μM CFSE for 10 min and the rest
CFSE was extensively removed. Subsequent, the cells were treated with 10 μM simvastatin
equivalent [S]-rHDL or nothing for 24 hours. The percentage of proliferating cells of the
total treated cells was determined by flow cytometry with a standard protocol.
Animals and diet
All animals were used based on an approved institutional protocol from Icahn School of
Medicine at Mount Sinai. 5 weeks old male apoE-KO mice (B6.129P2-Apoetm1Unc) were
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tpurchased from Jackson laboratory. All mice were fed with a high cholesterol diet,
containing 20.3% fat, 22.9% protein, 45.7% carbohydrate and 0.2% cholesterol (Research
Diets Inc., USA).
In vivo 9.4 Tesla MRI
To image the abdominal aortas, the mice were anesthetized and maintained by isoflurane
containing air, and were subsequently scanned with a 9.4 Tesla MRI system (Bruker
Instruments, Germany). T1-weighted MRI was performed using a black blood sequence.
Twenty-two consecutive 500 μm thick slices with 500 μm inter-slice distance were acquired
using a spin echo sequence with a 256X256 matrix size. A micro-scale in-plane resolution of
101 μm was achieved. The repetition time (TR) and echo time (TE) for the T1-weighted
scanning were 800 and 8.6 ms, respectively. An inflow saturation band of 3 mm was used
with a slice gap of 3 mm for additional luminal flow suppression. Sixteen signal averages
were used for a total imaging time of 55 min per scan. A saturation pulse was used to
eliminate signal from fat tissue and to delineate boundary of the aortic wall and minimize
chemical shift artifacts. To investigate the plaque targeting of [S]-rHDL, mice were first
subjected to baseline MRI scan, and subsequently injected through tail veins with a 50 μmol
Gadolinium/kg dose of the [Gd-S]-rHDL. The mice were scanned again at 24 hours post-
injection (N=3). Image analysis was done with semiautomatic software (VesselMass,
Leiden) to delineate the aortic lumen area (LA) and outer wall area (OWA). Mean wall area
(MWA) was defined as the difference between LA and OWA. The primary outcome
parameter was the normalized wall index (NWI), which was calculated as: NWI = MWA /
OWA. To evaluate the therapeutic effects of 12 week treatments, mice were scanned with
the same protocol but without the injection of contrast agents.
Ex vivo near infrared fluorescence imaging (NIRF)
The mice were injected through tail veins with Cy5.5-DMPE and DiR labeled [S]-rHDL
(N=3) or saline (N=3). At 24 hours post the injection, mice were sacrificed and perfused
with PBS. To acquire Cy5.5 signal from [S]-rHDL in tissues, aortas, hearts, livers, spleens
and kidneys were collected and imaged with IVIS 200 system (Xenogen) using 675(30) nm
excitation and 720 (20) nm emission filters. Photon counts were used to quantify the
fluorescence intensity from each tissue and it was reflected by color coded scale bar. Images
were processed with the integrated software from IVIS 200 (Living Imaging Software 4.0).
DiR signal was acquired with the same procedure but imaged at 745(30) nm excitation and
820 (20) nm emission filters.
Flow cytometry
To investigated the targeting mechanism of [S]-rHDL, apoE-KO mice were injected with
Cy5.5 and DiO dual-labelled [S]-rHDL at dose of 15 mg/kg simvastatin and 10 mg/kg
ApoA-1, the same as the low dose 12 week [S]-rHDL treatment. Mice were sacrificed at
individual time points post injection (hour 1, 2, 4, 6, 12 and 24; N=3 per time point). Blood
was collected and red blood cells were lysed and removed using red blood cell lysis buffer
(BD Biosciences). Mice were perfused with PBS and cells from aortas were collected using
the same method as described above. After perfusion with 30 ml of PBS, aortas were
collected and the surrounding adipose tissue was removed carefully without damaging the
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tadventitia. Aortas were digested with 4 U/ml liberase LH (Roche), 0.1 mg/ml DNase I
(Sigma-Aldrich), and 60 U/ml hyaluronidase (Sigma-Aldrich) in HBSS at 37°C for 90 min.
The suspension was incubated with a mixture of monoclonal antibodies for 30 min at 4 °C.
Fluorescence was detected by flow cytometer (BD Biosciences LSR II), and the data were
analyzed using FlowJO software (Tree Star). Macrophages from aortas were identified as
CD45+, CD11b+ and F4/80+, and monocytes were identified as CD45+, CD11b+, SSC-A
low cells. Based on the Gr-1 expression, monocytes in the blood were further identified as
Gr-1hi and Gr-1lo monocytes. To quantify the delivery efficiency to monocytes,
macrophages and neutrophils in the spleen, a recently reported protocol was used4. Briefly,
splenocytes were released by homogenizing the spleen and the tissue was digested with
collagenase (Sigma-Aldrich) for 30 min at 37°C. A cocktail of antibodies include a Pacific
blue-conjugated lineage (CD90 (clone 53-2.1), B220 (clone RA3-6B2), CD49b (clone
DX5), NK1.1 (clone PK136), Ly-6G (clone 1A8) and Ter-119 (clone TER-119)), Alexa700
conjugated CD11b (clone M1/70), APC-conjugated CD11c (clone HL3), PE-Cy7
conjugated F4/80 (clone BM8) and PE-conjugated Ly6C (clone AL-21). Neutrophils were
identified as Lineage high, CD11b high, ly-6c intermediate and SSC-A high. Macrophages
were identified as lineage -, CD11b high, and F4/80 +. Monocytes were identified as
Lineage -, CD11b high, CD11c −, F4/80 −, and Ly-6C +. Based on Ly-6c expression levels,
monocytes were further identified as Ly-6c high and Ly-6c low monocytes. All antibodies
were purchased from eBioscience, BD Biosciences and Biolegend and 1:200 dilution was
used.
Fluorescence quantification of blood components
ApoE-KO mice received dual-labeled [S]-rHDL (Cy5.5 and DiO) through tail veins
injection. At each individual time point (hour 1, 2, 4, 6, 12 and 24; N=3 per time point),
mouse blood was drawn by cardiac puncture and stored in EDTA containing tubes. 500 μl
blood was used for separating different compartments with Histopaque (Sigma-Aldrich,
Histopaque 1077) by following the instructions from the manufacturer. Briefly, the blood
and Histopaque solution was centrifuged at room temperature for 30 minutes, and three
compartments from the blood (serum; mononuclear cells; red blood cells and granulocytes)
were visible and collected. 50 μl solution from each compartment was added to 96-well plate
(3 repeats for each condition). The plate was imaged with IVIS 200 system (Xenogen). To
image DiO, excitation filter of 465 (30) nm and emission filter of 520 (20) nm were used. To
image Cy5.5, excitation filter of 675 (30) nm and emission filter to 720 (20) nm were used.
Signal intensity was analyzed and quantified using the integrated software from the system
(Living Imaging Software 4.0).
Immunohistochemistry and image quantification
Serial 6 μm thick cross-sections were made of the aortic sinus area on a cryotome (Reichert
HistoStat, Cryostat Microtome). From the first cross-section in which the leaflets of the
aortic valves appeared upward, 63 serial cross-sections were obtained, covering the entire
aortic sinus area. Of every 3 consecutive cross-sections, they were subjected to anti-CD68
immunohistochemical staining, hematoxylin phloxine saffron (HPS)-staining, and Oil Red
O-staining. HPS (HPS, polyscientific) and Oil Red O-staining (Fisher Scientific) were done
with standard methods. Anti-CD68-staining was done with a protocol previously reported37.
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anti-mouse CD68 primary antibody (Abdserotec, 1:250 dilution), 10 minutes with
biotinylated rabbit anti-rat antibody (Vectorlabs, 1:200 dilution), thereafter 5 minutes with
VECTASTAIN ABC-alkaline phosphatase solution (Vectorlabs), and finally for 17 minutes
with Vector Red solution (Vectorlabs).
All cross-sections were digitally imaged with a Nikon eclipse E400 microscope, with a 10x
eyepiece and 10x lenses, a Nikon DS-U1 camera box and Nikon DS-5M camera. We used
NIS-Elements F3.0 software, and imaged at a 1/350s exposure time, 2560 × 1920 pixels, and
pixel size of 1.46 μm2/ pix. Software written in Matlab was developed to facilitate
automated image analysis.
Treatment protocol
For the 12 weeks of treatment study, 6 week old male apoE-KO mice were fed a high
cholesterol diet (ResearchDiets, NJ) for 14 weeks, and subsequently received 12 weeks of
intravenous injection of [S]-rHDL (15 mg/kg simvastatin, 10 mg/kg ApoA-1, 2 injections/
week, N=16), intravenous injection of rHDL (10 mg/kg ApoA-1, 2 injections/week, N=16),
orally administered simvastatin (15 mg/kg/day, 2 saline intravenous injections/week, N=15)
and placebo (2 saline injections/week, N=15). Mice were kept on a high fat diet during the
12 weeks treatment. Another group of mice (N=12) were sacrificed when the other groups
started their 12 week treatment to establish a baseline. 8 mice per group were imaged with
MRI over abdominal aortas before, in the middle and by the end of the 12 weeks treatments.
For one week short-term treatment study, 6 week old male apoE-KO mice were fed a high
cholesterol diet for 27 weeks. After the diet, mice were injected intravenously with high
dose [S]-rHDL (60 mg/kg simvastatin, 40 mg/kg ApoA-1, 4 injections /week), high dose
rHDL (40 mg/kg ApoA-1, 4 injections /week), low dose [S]-rHDL (15 mg/kg simvastatin,
10 mg/kg ApoA-1, 4 injections /week) or placebo (4 saline injections/week).
Laser capture microdissection and qRT-PCR
36 male apoE KO mice with 6 weeks were fed a high fat diet for 26 weeks to develop
advanced atherosclerosis. The animals received one week treatment of high dose [S]-rHDL
(4 i.v. infusions of 60 mg/kg statin, 40 mg/kg ApoA1, denoted as “high [S]-rHDL), rHDL (2
i.v. infusions of 10 mg/kg ApoA1, denoted as “rHDL”), oral statin treatment (15 mg/kg/day
oral simvastatin, denoted as “Oral SVS”), rHDL plus oral statin (15 mg/kg/day oral
simvastatin and 2 i.v. infusions of 10 mg/kg ApoA1, denoted as “rHDL + Oral SVS”), or
placebo (4 i.v. injections of PBS). Sections from aortic roots are prepared as described
above, and a total of 24 sections were made per animal. For every 8 consecutive sections,
the first one was stained with CD68 with the same method described above and used as the
guiding section. The other 7 sections were used for isolating macrophages using laser
capture microdissection (LCM) as previously described35. Briefly, the sections were fixed in
70% ethanol for 1 min, washed in H2O, stained with Mayer’s hematoxylin (VWR Scientific)
for 1 min, washed in H2O, incubated in PBS (to develop blue color) for 15 seconds, washed
in H2O, partially dehydrated in 70% followed by 95% ethanol, stained in eosin Y (VWR
Scientific) for 5 seconds, washed in 95% ethanol, and completely dehydrated in 100%
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tethanol (30 seconds), xylene (30 sec) and xylene (5 minutes). After air-drying for 10 min,
macrophages were identified under a microscope and be verified by the CD68 staining on
the guiding slides. Several hundred macrophages per mouse were collected, and these
macrophages from each animal were used to extract and amplify RNA with WT-Ovation
Pico RNA amplification system (NuGen). The quality of extracted RNA was measured by
Agilent 2100 Bioanalyzer. Quantitative Reverse Transcriptase PCR (qRT-PCR) was
performed on samples using the iScript cDNA Synthesis kit (Bio Rad) according to
manufacturer’s protocol. The mRNA expression levels of investigated genes were
normalized to housekeeping gene hprt1 (UniGene ID: Mm.1037830). The following genes
were investigated: MCP-1 (Mm.290320), CCL-3 (Mm.1283), ICAM-1 (Mm.435508),
VACM-1 (Mm.440909), CXCL12 (Mm.303231), CCL15 (Mm.284348), TNF-α (Mm.
1293), IL-1β (Mm.222830), IL-1α (Mm.15534), Spp1 (Mm.288474), MR (Mannose
Receptor, Mm2019). TaqMan Gene Expression assay (Life Technologies, Cat. NO.
4331182) was used to measured the gene expression on sequence detection device (ABI
PRISM 7900HT).
Fluorescence molecular tomography with CT
Eleven 6 week old apoE-KO mice were fed a high fat diet for 20 weeks before receiving 4
high dose [S]-rHDL or placebo (PBS) injections in a week. Five nmol of pan-cathepsin
protease sensor (ProSense 680, PerkinElmer, Cat# NEV10003) was intravenously
administered along with the last intravenous injection of [S]-rHDL or PBS. 24 hours later
the animals were placed in a custom-built imaging cartridge which was equipped for
isoflurane administration during imaging. Animals were first scanned with high-resolution
computated tomography (CT; Inveon PET-CT, Siemens), with a continuous infusion of CT-
contrast agent (isovue-370, Bracco Diagnostics) at a rate of 55 μl/min through a tail-vein
catheter. Animals were subsequently scanned with an FMT scanner (PerkinElmer) in the
same cartridge. The CT x-ray source with an exposure time of 370–400 ms was operated at
80kVp and 500 μA. Contrast-enhanced high resolution CT images were used to localize the
aortic root, which was used to guide the placement of the volume of interest for the
quantitative FMT protease activity map. The CT reconstruction protocol involved bilinear
interpolation, used a Shepp-Logan filter, and scaled pixels to Hounsfiled units. Image fusion
relied on fiducial markers and used Osirix software (The Osirix Foundation, Geneva).
Blood tests and lipoprotein analysis
After 4 hours of fasting, whole blood was collected in EDTA containing tube. Some serum
was subjected to a biochemistry panel (ALX laboratories, NY) analysis to determine the
blood concentrations of alanine transaminase, aspartate transaminase, creatinine, creatine
kinase, cholesterol and triglyceride. The rest serum was pooled per group for lipoprotein
analysis via fast performance liquid chromatography (FPLC) (Pharmacia). For each sample,
250 μl of plasma was applied to 2 Superose 6 columns (GE healthcare) equilibrated and run
in a buffer containing 150 mM NaCl and 15 mM EDTA in deionized water. The column
flow rate was 0.7 mL/min. 80 fractions were collected, and the total cholesterol
concentration of each fraction was assessed by enzymatic colorimetric assay (Wako)
according to the manufacturer’s instructions.
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The thoracic aortas were blotted dry and weighed. Later, they were minced and extracted
with chloroform/methanol (2:1) according to the method of Folch et al.36 The cholesterol
containing supernatant was measured (WACO diagnostics) and the total cholesterol from the
aortas was calculated accordingly. Finally, the ratio of cholesterol to tissue was calculated
by dividing the total cholesterol content per aorta by the weight of the aorta.
Statistics
Continuous variables are expressed as means ± standard deviation, unless otherwise stated.
Significance of differences was calculated by use of the nonparametric Mann-Whitney U
tests and Kruskal-Wallis tests. Multiple linear regression analysis was used to assess the
association between CD68 area and the various treatment groups, with CD68 area as the
response variable and treatment group as the explanatory variable, adjusting for the potential
confounder serum total cholesterol. Composite variables were calculated for monocyte
recruitement and pro-inflammatory mRNA expression in the LCM experiment. Probability
values of P<0.05 were considered significant. Statistical analyses were done using SPSS
(Statistical Package for the Social Sciences) version 17.0 and SAS package (SAS Institute
Inc.).
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Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. Schematic of the study design
(a) The targeting dynamics, targeting mechanism and anti-inflammatory action of [S]-rHDL in apoE-KO mice were investigated
by analyzing the dynamics of phospholipids and hydrophobic cargos of [S]-rHDL in the blood by NIRF and flow cytometry.
The biodistribution was evaluated in organs with NIRF. (b) Magnetic resonance imaging (MRI), near infrared fluorescence
imaging (NIRF), fluorescence microscopy, and flow cytometry were used to validate the plaque macrophage targeting efficiency
of [S]-rHDL. The effect of [S]-rHDL on the mRNA levels of inflammatory genes of plaque macrophages were determined in
macrophages isolated with laser capture microdissection. Fluorescence molecular tomography and computed tomography was
used to assess the effect of [S]-rHDL on inflammatory protease activity in aortic root plaques. (c) The efficacy of low-dose long-
term (12 weeks) [S]-rHDL treatment on disease progression was evaluated in the abdominal aortas with MRI and in aortic roots
with histology. (d) The efficacy of high-dose short-term (1 week) [S]-rHDL treatment was evaluated in aortic roots with
histology.
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tFigure 2. Schematic representations of the nanoparticle formulations and in vitro efficacy data
(a) Schematic representation of dual gadolinium and fluorescent dye (Cy5.5, DiO, DiR) labeled statin containing reconstituted
high density lipoprotein ([Gd-dye-S]-rHDL), statin containing rHDL ([S]-rHDL), and rHDL. Negative staining transmission
electron microscopy (TEM) images of each of the aforementioned particles showed the typical disk-like morphology. The
circular shapes are nanoparticles viewed en face, while the striped configurations are rouleaux of nanoparticles viewed from the
side. Dynamic light scattering measurements showed the average size of [Gd-dye-S]-rHDL to be 28.5 nm, of [S]-rHDL to be
26.0 nm and of rHDL to be 10.5 nm. For larger view TEM also see Supplementary Fig. S1. (b) In vitro cell viability assays of
murine macrophages (J774A.1), incubated with combinations of [S]-rHDL (10 μM statin) free simvastatin (10 μM), rHDL plus
free statin (10 μM), free statin (10 μM) plus mevalonate (100 μM), [S]-rHDL (10 μM) plus mevalonate (100 μM), and only
mevalonate (100 μM). There was also a control group of cells not incubated with anything. Macrophage cell viability is
markedly decreased in the [S]-rHDL and free statin group. This effect is abolished by addition of mevalonate, indicating that the
effect of HMGR inhibition on cell viability is mediated through the mevalonate pathway. N=6 for all bars. (c) Production of the
inflammatory cytokines MCP-1 and TNF-α. LPS and INF-γ challenged macrophages were incubated with the same treatments
as mentioned above for 24 hours. MCP-1 and TNF-α levels are markedly reduced by [S]-rHDL and free statin. MCP-1 and
TNF-α levels are restored by the addition of mevalonate to [S]-rHDL and free statin incubation. N=6 for all bars. Cell viability
in the different groups was not affected under these conditions (Supplementary Fig. S4). All error bars are 95% confidence
intervals. P-values are calculated with Mann-Whitney U tests for comparisons with [S]-rHDL, * indicates P < 0.05, ** indicates
P < 0.01. Kruskal-Wallis P-values are < 0.0001 for all plots.
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tFigure 3. Pharmacokinetics and accumulation in plaque of labeled nanoparticles
(a) Cy5.5- and DiO-labelled [S]-rHDL was intravenously injected to apoE-KO mice (N=21, 3 mice per time point) and blood
and tissues were analyzed at different time points post-injection. NIRF shows that components from the lipid monolayer (Cy5.5)
have much shorter blood half-life than components from hydrophobic core (DiO). It also shows that the majority of [S]-rHDL
stays in serum and very little in red blood cells (RBC) and mononuclear cells (MNC). (b) Fluorescence intensity in serum,
MNC, and RBC is quantified (N=21, 3 mice per time point). We calculated that plasma half-life of [S]-rHDL to be 21.9 hours
for the DiO signal. (c) Flow cytometric analysis of blood cells shows that [S]-rHDL targets Gr-1hi pro-inflammatory monocytes
more efficiently than Gr-1lo anti-inflammatory monocytes in blood (N=21, 3 mice per time point). (d) Typical T1-weighted 9.4
Tesla magnetic resonance images of the abdominal aorta of an apoE-KO mouse, made at identical locations, before and 24 hours
after injection of [Gd-Dye-S]-rHDL. The lumen is indicated by *. The scale bar in the upper images represent 10 mm, and in the
lower images 1 mm. The 24h post-injection image showed signal enhancement in the vessel wall (white arrows), indicative of
nanoparticle infiltration and retention in the aortic plaques. (e) [S]-rHDL labeled with Cy5.5 (lipid monolayer) and DiR
(hydrophobic core) was intravenously injected to apoE-KO mice. NIRF shows that Cy5.5 and DiR preferentially accumulates in
the areas rich with atherosclerotic lesions. The scale bar represent 10 mm. (f) Cy5.5 and DiO both appear in the plaque, until 4
hours post-injection the presence of Cy5.5 declines while DiO remains present. The scale bar represents 500 μm. (g) DiO-
labelled [S]-rHDL co-localizes in the plaque with CD68 (macrophages). The scale bar in the inset represent 100μm, and in the
overview 400 μm (h) Flow cytometric analysis of cells in aorta walls shows that [S]-rHDL is taken up by plaque macrophages,
furthermore, macrophages are targeted more efficiently than monocytes (N=3 per timepoint). All error bars are standard errors
of the mean.
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tFigure 4. In vivo efficacy of 12 weeks biweekly low dose [S]-rHDL infusions
(a) Efficacy of [S]-rHDL on abdominal atherosclerosis quantified by 9.4 Tesla magnetic resonance imaging (9.4T-MRI).
Typical T1-weighted MR images of the abdominal aortas of mice in each group at all time points show the thickening of the
aorta wall in all groups except in the [S]-rHDL-treated group. The analysis method of the images is shown in Supplementary
Fig. S9. The scale bar represents 1 mm. (b) MRI scans of the abdominal aortas of 32 mice (N=8 per group) were performed at
three time points during the study. When the apoE-KO mice were 14 weeks on high cholesterol diet the baseline scans were
acquired and subsequent scans were performed 6 and 12 weeks after the baseline scan. From baseline onwards the mice received
placebo, oral statin therapy, or injections of reconstituted high-density lipoprotein (rHDL) or statin containing rHDL ([S]-
rHDL). Thickness of the vessel wall is expressed as the normalized wall index (NWI), which is defined as the ratio between the
mean wall area and the outer wall area. (c) Efficacy of [S]-rHDL assessed by histology shows that mean plaque area was lower
in the [S]-rHDL treated group (N=15) as compared to placebo (N=16) and rHDL (N=16), and there was a trend towards
decreased plaque area compared to statin therapy (N=15). Kruskal-Wallis P-value for plaque area is 0.0011. (d) Plaque
macrophage content as measured by the CD68 positive area was decreased in the [S]-rHDL group (N=15) as compared to
placebo- (N=16), statin- (N=15) and rHDL-therapy (N=16), indicating decreased plaque inflammation in the [S]-rHDL group.
Bars represent the standard error of the mean, P-values were calculated with Mann-Whitney U tests. Kruskal-Wallis P-value for
CD68 area is 0.0001. (e) Typical histology images of the aortic sinus area of each group are shown. The hematoxylin phloxine
saffron (HPS)-stained images are shown on the left and the cross-sections stained with CD68 antibodies are shown on the right.
The analysis method of the histology images is shown in Supplementary Fig. S9. The scale bar represents 400 μm.
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tFigure 5. In vivo efficacy of a single week high dose [S]-rHDL infusions
(a) Mean plaque area was lower in the high dose [S]-rHDL-treated group (N=10) as compared to placebo (N=15), high dose
rHDL (N=8), and low dose [S]-rHDL(N=10). Kruskal-Wallis P-value for plaque area is 0.037. (b) Plaque macrophage content
as measured by the CD68 positive area was decreased in the high dose [S]-rHDL (N=10) as compared to placebo (N=15), high
dose rHDL (N=8), and low dose [S]-rHDL (N=10), indicative of decreased plaque inflammation in this group. Bars represent
the standard error of the mean, P-values were calculated with Mann-Whitney U tests. Kruskal-Wallis P-value for CD68 area is
0.0006. (c) Typical histology images of the aortic sinus area from a mouse in the placebo group and a mouse in the high dose
[S]-rHDL-group show that mean plaque area is similar, while the plaque macrophage content is notably smaller in the [S]-
rHDL-group. The hematoxylin phloxine saffron (HPS)-stained images are shown on the left and the cross-sections stained with
CD68 antibodies are shown on the right. The scale bar represents 400 μm. (d) One-week high dose [S]-rHDL treatment (N=6)
significantly reduced the mRNA expression levels of monocyte recruitment genes (composite variable of MCP-1, CCL-3,
ICAM-1, VCAM-1, CCL-15, CXCL-12) and pro-inflammatory genes (composite variable of TNF-α, IL-1β, IL-1α, SPP-1) of
plaque macrophages in the aortic root when compared to placebo (N=6) and oral statin (N=6). The expression of the anti-
inflammatory mRNA level (MR) was increased in the high dose [S]-rHDL group as compared to placebo, but not compared to
oral statin therapy. P-values are calculated with Mann-Whitney U tests for comparisons with [S]-rHDL, * indicates P < 0.05, **
indicates P < 0.01. Kruskal-Wallis P-values are shown in the plot. The error bars represent the standard deviations. (e) FMT-CT
molecular imaging of protease activity revealed that high dose [S]-rHDL treatment (N=6) significantly reduced the
inflammation levels in the aortic roots of live apoE-KO mice with advanced atherosclerosis as compared to placebo (N=5). The
yellow circles indicate the aortic root area. The error bars represent the standard error of the mean. P-values were calculated with
the Mann-Whitney U test.
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